Feb 25 2010
Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, and its wholly owned subsidiary Xenogen Corporation, today announced the filing of a patent infringement lawsuit in the U.S. District Court for the Eastern District of Texas.
In the suit, filed with Stanford as a co-plaintiff, Caliper Life Sciences and Xenogen seek a finding of willful infringement by Carestream Health, Inc. of Rochester, NY, compensatory damages, a trebling due to willfulness, a permanent injunction and attorneys' fees against Carestream for the ongoing, unauthorized and willful use of a number of United States patents that Caliper, through Xenogen, exclusively licenses from Stanford University.
The seven patents in-suit (which comprise a portion of Caliper's "Optical Imaging Patent Suite™") encompass methods for non-invasive in vivo imaging of fluorescence and bioluminescence in animals. Researchers licensed under Caliper's Optical Imaging Patent Suite are uniquely enabled by Caliper's novel imaging systems and method patents in fields such as identifying disease pathways, determining mechanisms of action, evaluating drug compounds, and monitoring a compound's effects on disease progression in living animals. To date, more than 1300 peer-reviewed research articles that utilized Caliper's IVIS imaging systems have been published, demonstrating the critical role of Caliper's imaging systems and the patented imaging methods in furthering research and aiding the development of lifesaving therapies.
Caliper Life Sciences, Inc. and Xenogen Corporation are represented in this litigation by Washington, DC-based intellectual property specialty law firm Sterne, Kessler, Goldstein & Fox P.L.L.C. and Tyler, TX-based litigation firm Wilson, Robertson & Cornelius, P.C.
SOURCE Caliper Life Sciences, Inc.
BMI's influence on disease pathogenesis uncovered in new research